ADMA Biologics バランスシートの健全性
財務の健全性 基準チェック /66
ADMA Biologicsの総株主資本は$231.9M 、総負債は$101.3Mで、負債比率は43.7%となります。総資産と総負債はそれぞれ$390.6Mと$158.7Mです。 ADMA Biologicsの EBIT は$117.7Mで、利息カバレッジ比率7.8です。現金および短期投資は$86.7Mです。
主要情報
43.7%
負債資本比率
US$101.33m
負債
| インタレスト・カバレッジ・レシオ | 7.8x |
| 現金 | US$86.71m |
| エクイティ | US$231.89m |
| 負債合計 | US$158.73m |
| 総資産 | US$390.62m |
財務の健全性に関する最新情報
Is ADMA Biologics (NASDAQ:ADMA) Using Too Much Debt?
Jul 17
Is ADMA Biologics (NASDAQ:ADMA) A Risky Investment?
Apr 04We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt
Oct 25We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt
Jun 10ADMA Biologics (NASDAQ:ADMA) Is Carrying A Fair Bit Of Debt
Jun 01Recent updates
ADMA Biologics, Inc.'s (NASDAQ:ADMA) 27% Price Boost Is Out Of Tune With Revenues
Oct 09ADMA Biologics: Riding High On ASCENIV's Success
Oct 02ADMA Biologics, Inc.'s (NASDAQ:ADMA) Intrinsic Value Is Potentially 57% Above Its Share Price
Sep 06ADMA Biologics' (NASDAQ:ADMA) Strong Earnings Are Of Good Quality
Aug 16ADMA Biologics: A Compelling GARP Stock For Biotech Investors
Jul 27ADMA Biologics, Inc. (NASDAQ:ADMA) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected
Jul 24Is ADMA Biologics (NASDAQ:ADMA) Using Too Much Debt?
Jul 17Is ADMA Biologics, Inc. (NASDAQ:ADMA) Trading At A 43% Discount?
May 30ADMA Biologics, Inc. Just Beat EPS By 45%: Here's What Analysts Think Will Happen Next
May 13Giving ADMA Biologics A Well-Deserved 'Booyah'
May 12ADMA Biologics, Inc.'s (NASDAQ:ADMA) Prospects Need A Boost To Lift Shares
May 08Is ADMA Biologics (NASDAQ:ADMA) A Risky Investment?
Apr 04Rising Margins And Product Promise Drive ADMA Biologics Forward (Rating Upgrade)
Apr 03ADMA Biologics: On A Roll Entering 2024
Jan 19Is There An Opportunity With ADMA Biologics, Inc.'s (NASDAQ:ADMA) 50% Undervaluation?
Jan 09ADMA Biologics, Inc. (NASDAQ:ADMA) Surges 30% Yet Its Low P/S Is No Reason For Excitement
Jan 09We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt
Oct 25We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt
Jun 10The Market Doesn't Like What It Sees From ADMA Biologics, Inc.'s (NASDAQ:ADMA) Revenues Yet
May 12ADMA Biologics: Strong Growth Is Clearing The Path To Profitability
Aug 21ADMA Biologics GAAP EPS of -$0.07, revenue of $33.9M
Aug 10ADMA Biologics (NASDAQ:ADMA) Is Carrying A Fair Bit Of Debt
Jun 01ADMA Biologics: A Path To Profits Looks Clear
May 12ADMA: Pertinent Updates
Apr 18ADMA Biologics' 2021 Numbers Showed Continued Strong Execution
Mar 29財務状況分析
短期負債: ADMAの 短期資産 ( $318.2M ) が 短期負債 ( $44.9M ) を超えています。
長期負債: ADMAの短期資産 ( $318.2M ) が 長期負債 ( $113.8M ) を上回っています。
デット・ツー・エクイティの歴史と分析
負債レベル: ADMAの 純負債対資本比率 ( 6.3% ) は 満足できる 水準であると考えられます。
負債の削減: ADMAの負債対資本比率は、過去 5 年間で229.1%から43.7%に減少しました。
債務返済能力: ADMAの負債は 営業キャッシュフロー によって 十分にカバー されています ( 84.9% )。
インタレストカバレッジ: ADMAの負債に対する 利息支払い は EBIT ( 7.8 x coverage) によって 十分にカバーされています。